Result of Annual General Meeting

RNS Number : 9334S

Redx Pharma plc

14 March 2023

 

REDX PHARMA PLC

("Redx" or "the Company")

Result of Annual General Meeting

Alderley Park, UK, 14 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease announces that its Annual General Meeting was held at 11am on 14 March 2023, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders

Resolution number	Resolution name	Number of votes for & discretionary	% of votes for & discretionary	Number of votes against	% of votes against	% of votes withheld*	Total votes cast (including withheld)
1	Receive the Company's annual accounts	306,243,523	94.91%	16,434,331	5.09%	0.00%	322,680,605
2	Re-appoint Ernst & Young as auditors	322,677,854	100.00%	2,751	0.00%	0.00%	322,680,605
3	Re-elect Dr Bernhard Kirschbaum as a director	306,241,648	94.91%	16,436,206	5.09%	0.00%	322,680,605
4	Re-elect Lisa Anson as a director	322,678,730	100.00%	1,875	0.00%	0.00%	322,680,605
5	Re-elect Natalie Berner as a director	322,673,730	100.00%	6,875	0.00%	0.00%	322,680,605
6	Authorise the directors to allot shares	322,551,347	99.96%	125,732	0.04%	0.00%	322,680,605
7	Disapply pre-emption rights	322,545,847	99.96%	133,983	0.04%	0.00%	322,680,605

*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'

For further information, please contact:
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications  [e-mail] Lisa Anson, Chief Executive Officer		T: [phone]
US Office Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)		T: [phone]
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker)		T: [phone]
Claes Spång/ Satheesh Nadarajah/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker)		T: [phone]
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting		T: [phone]
Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022, with topline data expected in Q1 2024. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report both monotherapy and combination with anti-PD-1 Phase 2 data during 2023.  Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023. 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration. 

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/  

 

END

 

 

RAGDZGMFMDMGFZM